Obstructive sleep apnea (OSA)

What changes during this transition

Obstructive sleep apnea is a PSG-diagnosed mechanical disease: the upper airway collapses repeatedly during sleep, producing the apnea-hypopnea index (AHI) that grades severity — ≥5 events/hour with symptoms is mild, ≥15 is moderate, ≥30 is severe. It is distinct from central sleep apnea (which is a respiratory-drive disease, not an airway-collapse disease) and from chronic insomnia (which is a sleep-initiation and maintenance problem, not a breathing-disordered-sleep problem). Roughly a quarter of US adults are affected; most are undiagnosed. Standard-of-care is well-established. CPAP (continuous positive airway pressure) has been Tier 1 since 1981 — it pneumatically splints the airway open, normalizes AHI, has the deepest cardiovascular-outcome evidence in OSA, and its central clinical problem is long-term adherence (~50% by most large-cohort estimates). Oral appliances (mandibular advancement devices) are first-line for mild-to-moderate disease or CPAP-intolerant patients. Positional therapy applies when OSA is position-dominant. Surgical options include UPPP (uvulopalatopharyngoplasty), MMA (maxillomandibular advancement), and the Inspire hypoglossal-nerve stimulator (FDA 2014) for CPAP-intolerant moderate-to-severe disease. Weight loss has been a long-standing recommendation; until 2024, the pharmacological evidence base was essentially absent and significant weight loss meant bariatric surgery for severe cases. The paradigm shift: SURMOUNT-OSA (Malhotra 2024 NEJM, NCT05412004) — n=469 adults with PSG-confirmed moderate-to-severe OSA + obesity (BMI ≥30), tirzepatide 10mg or 15mg weekly vs placebo for 52 weeks across both CPAP-using and CPAP-naive arms — produced an AHI reduction of ~25–29 events per hour (about 50–60% from baseline) alongside ~17–19% weight loss and improvements in BP, hsCRP, and sleep-related quality of life. The FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA + obesity in June 2025 — the first pharmacological treatment ever approved for OSA, and the first GLP-1-family drug to get an OSA indication. Tirzepatide is surfaced here on that basis. Semaglutide is surfaced as a strong-mechanism-case adjacent option: SELECT and STEP-program weight-loss data predict OSA-symptom improvement through the same upper-airway-fat-reduction mechanism, secondary analyses show real signal on snoring + sleepiness + Berlin scores, but no dedicated OSA Phase 3 with an AHI primary endpoint has reported as of mid-2026 — semaglutide for OSA + obesity is prescribed on the obesity or CVD indication, not the OSA indication. What is NOT surfaced and why. Tesamorelin: real visceral-fat-reduction signal in HIV-associated lipodystrophy, indirect OSA implications in that narrow subpopulation, but no OSA trial and the indication doesn't propagate (Rule 6) — substrate exists for the HIV-OSA-overlap question, not for general OSA discovery. CJC-1295: community framing about 'GH peptides improve sleep architecture' conflates slow-wave-sleep biology in GH-deficient adults with obstructive-sleep-apnea biology, which is a mechanical airway-collapse disease that GHRH stimulation doesn't address — substrate exists to redirect that confusion, not to elevate it. MK-677: appetite-stimulating, weight-gain-inducing, fluid-retention-causing, insulin-resistance-worsening — every effect runs the opposite direction from what OSA treatment is trying to accomplish — substrate exists with a safety thread, not as a discovery option.